Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    TCD12012
Show Display Options
Rank Status Study
1 Completed Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Subjects With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia
Conditions: Indolent Non-Hodgkin Lymphoma;   Mantle Cell Lymphoma;   Chronic Lymphocytic Leukemia
Intervention: Drug: SAR245409

Indicates status has not been verified in more than two years